Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron M Koenig

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Treatment Options in Psychiatry|March 26, 2014
Cognition in Late Life Depression: Treatment ConsiderationsAaron M Koenig, Meryl A Butters
Polskie Archiwum Medycyny Wewnetrznej|September 25, 2009
First-line pharmacotherapies for depression - what is the best choice?Aaron M Koenig, Michael E Thase
Journal of the International Neuropsychological Society : JINS|April 2, 2014
Cognitive functioning and late-life depressionAaron M Koenig, Rishi K Bhalla, Meryl A Butters
Current Psychiatry Reports|December 24, 2015
Agitation and Irritability in Alzheimer's Disease: Evidenced-Based Treatments and the Black-Box WarningAaron M Koenig, Steven E Arnold, Joel E Streim
Focus (American Psychiatric Publishing)|January 25, 2020
Biomarkers in Alzheimer's, Frontotemporal, Lewy Body, and Vascular DementiasAaron M Koenig, Chloe K Nobuhara, Victoria J Williams, et al.
Medical Devices (Auckland, N.Z.)|February 3, 2018
Physician preference items: what factors matter to surgeons? Does the vendor matter?Lawton R Burns, Michael G Housman, Robert E Booth, et al.
Behavior Therapy|April 1, 2014
Extreme nonresponse to acute phase cognitive therapy for depression: an attempt to replicate and extendAaron M Koenig, Robin B Jarrett, Robert Gallop, et al.
The Journal of Clinical Psychiatry|March 8, 2014
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioningAaron M Koenig, Meryl A Butters, Amy Begley, et al.
Plos One|March 6, 2018
The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's diseaseBianca A Trombetta, Becky C Carlyle, Aaron M Koenig, et al.
Alzheimer Disease and Associated Disorders|May 25, 2017
Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover StudyAaron M Koenig, Dawn Mechanic-Hamilton, Sharon X Xie, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Treatment Options in Psychiatry|March 26, 2014
Cognition in Late Life Depression: Treatment ConsiderationsAaron M Koenig, Meryl A Butters
Polskie Archiwum Medycyny Wewnetrznej|September 25, 2009
First-line pharmacotherapies for depression - what is the best choice?Aaron M Koenig, Michael E Thase
Journal of the International Neuropsychological Society : JINS|April 2, 2014
Cognitive functioning and late-life depressionAaron M Koenig, Rishi K Bhalla, Meryl A Butters
Current Psychiatry Reports|December 24, 2015
Agitation and Irritability in Alzheimer's Disease: Evidenced-Based Treatments and the Black-Box WarningAaron M Koenig, Steven E Arnold, Joel E Streim
Focus (American Psychiatric Publishing)|January 25, 2020
Biomarkers in Alzheimer's, Frontotemporal, Lewy Body, and Vascular DementiasAaron M Koenig, Chloe K Nobuhara, Victoria J Williams, et al.
Medical Devices (Auckland, N.Z.)|February 3, 2018
Physician preference items: what factors matter to surgeons? Does the vendor matter?Lawton R Burns, Michael G Housman, Robert E Booth, et al.
Behavior Therapy|April 1, 2014
Extreme nonresponse to acute phase cognitive therapy for depression: an attempt to replicate and extendAaron M Koenig, Robin B Jarrett, Robert Gallop, et al.
The Journal of Clinical Psychiatry|March 8, 2014
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioningAaron M Koenig, Meryl A Butters, Amy Begley, et al.
Plos One|March 6, 2018
The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's diseaseBianca A Trombetta, Becky C Carlyle, Aaron M Koenig, et al.
Alzheimer Disease and Associated Disorders|May 25, 2017
Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover StudyAaron M Koenig, Dawn Mechanic-Hamilton, Sharon X Xie, et al.
Pageof 2